Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: the Kenyan experience.

Sayed S, Moloo Z, Bird P, Wasike R, Njoroge W, Karanu J, Nzioka A, Sherman O, Prasad S, Mariwa C, Otieno JO, Chumba D, Koech D, Mbinga D, Mohammed M, Njoroge R, Chauhan R, Vinayak S, Kyobutungi C, Saleh M.

J Clin Pathol. 2013 Apr;66(4):307-11. doi: 10.1136/jclinpath-2012-201404. Epub 2013 Feb 1.

PMID:
23378268
2.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

3.

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

J Clin Oncol. 2008 Mar 20;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565. Epub 2008 Feb 19.

PMID:
18285604
4.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
5.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
6.

Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.

Gentilini O, Masullo M, Rotmensz N, Peccatori F, Mazzarol G, Smeets A, Simsek S, De Dosso S, Veronesi P, Intra M, Zurrida S, Viale G, Goldhirsch A, Veronesi U.

Eur J Surg Oncol. 2005 Apr;31(3):232-6.

PMID:
15780556
7.

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, Nakano S, Fukutomi T, Hara K, Ichihara S, Lin Y, Kikuchi S.

J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.

PMID:
19946706
8.

Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.

Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens MR, Vergote I, Van Huffel S, Neven P.

J Clin Oncol. 2010 Sep 20;28(27):4129-34. doi: 10.1200/JCO.2009.26.4200. Epub 2010 Aug 16.

PMID:
20713855
9.

High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.

Ly M, Antoine M, Dembélé AK, Levy P, Rodenas A, Touré BA, Badiaga Y, Dembélé BK, Bagayogo DC, Diallo YL, Koné AA, Callard P, Bernaudin JF, Diallo DA.

Oncology. 2012;83(5):257-63. doi: 10.1159/000341541. Epub 2012 Sep 4.

PMID:
22964749
10.

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31.

PMID:
21452022
11.

[Biological features of breast cancer in patients under 35].

Damenia AO, Turkevich EA, Semiglazov VF, Kochetova IA, Gurbanov SS, Bit-Sava EM, Efimenko AV.

Vopr Onkol. 2007;53(6):674-6. Russian.

PMID:
18416136
12.

Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.

Richter-Ehrenstein C, Müller S, Noske A, Schneider A.

Int J Surg Pathol. 2009 Aug;17(4):323-6. doi: 10.1177/1066896908327576. Epub 2008 Nov 24.

PMID:
19029173
13.
14.
15.

Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.

Sutela A, Vanninen R, Sudah M, Berg M, Kiviniemi V, Rummukainen J, Kataja V, Kärjä V.

Acta Oncol. 2008;47(1):38-46.

PMID:
17851859
16.
17.

HER2 as a prognostic factor in breast cancer.

Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.

Oncology. 2001;61 Suppl 2:67-72. Review.

PMID:
11694790
18.

Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.

Boland GP, McKeown A, Chan KC, Prasad R, Knox WF, Bundred NJ.

Br J Cancer. 2003 Jul 21;89(2):277-83.

19.

Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.

Aryandono T, Harijadi, Ghozali A.

Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:600-6.

PMID:
10895217
20.

Supplemental Content

Support Center